These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years. Gonsette RE; Demonty L; Delmotte P J Neurol; 1977 Feb; 214(3):173-81. PubMed ID: 65452 [TBL] [Abstract][Full Text] [Related]
6. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. Likosky WH; Fireman B; Elmore R; Eno G; Gale K; Goode GB; Ikeda K; Laster J; Mosher C; Rozance J J Neurol Neurosurg Psychiatry; 1991 Dec; 54(12):1055-60. PubMed ID: 1783915 [TBL] [Abstract][Full Text] [Related]
7. Effect of lymphocytapheresis plus cyclophosphamide on the course of a chronic progressive form of multiple sclerosis. Ferla S; Meneghetti G; Spartà S; Belloni M; Ongaro G Ital J Neurol Sci; 1985 Sep; 6(3):283-6. PubMed ID: 4066266 [TBL] [Abstract][Full Text] [Related]
8. 24-month follow-up of multiple sclerosis patients treated with cyclophosphamide. Millefiorini E; Di Giovanni M; Bernardi S; Grasso MG; Di Giampietro A; Gambi D Ital J Neurol Sci; 1990 Dec; 11(6):605-7. PubMed ID: 2081686 [TBL] [Abstract][Full Text] [Related]
13. [The comparison of the effectiveness of treatment of multiple sclerosis relapse with high doses of methylprednisolone, alpha-24 corticotropin and cyclophosphamide]. Paradowski B; Gruszka E; Pokryszko A Pol Merkur Lekarski; 1999 Jun; 6(36):305-7. PubMed ID: 10481540 [TBL] [Abstract][Full Text] [Related]
14. [Late results of the treatment of the chronic progressive form of multiple sclerosis by intensive immunosuppression]. Wender M; Tokarz-Kupczyk E; Mularek O Neurol Neurochir Pol; 1989; 23(3):188-92. PubMed ID: 2561379 [TBL] [Abstract][Full Text] [Related]
15. [Immunosuppressive treatment in multiple sclerosis]. Vermeulen M; Zegerius L; van Crevel H Ned Tijdschr Geneeskd; 1987 Jan; 131(3):93-6. PubMed ID: 3821989 [No Abstract] [Full Text] [Related]
16. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994 [TBL] [Abstract][Full Text] [Related]
17. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094 [TBL] [Abstract][Full Text] [Related]
18. Immunosuppression and plasmapheresis in chronic progressive multiple sclerosis. Design of a clinical trial. Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Weiner HL Arch Neurol; 1983 Oct; 40(11):687-90. PubMed ID: 6354151 [No Abstract] [Full Text] [Related]
19. The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. Lamers KJ; Uitdehaag BM; Hommes OR; Doesburg W; Wevers RA; von Geel WJ J Neurol Neurosurg Psychiatry; 1988 Oct; 51(10):1334-7. PubMed ID: 2465387 [TBL] [Abstract][Full Text] [Related]
20. Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. Patti F; Reggio E; Palermo F; Fiorilla T; Politi G; Nicoletti A; Reggio A J Neurol; 2004 Dec; 251(12):1502-6. PubMed ID: 15645351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]